Panacos Pharmaceuticals Inc. Presents Data At 13th Conference On Retroviruses And Opportunistic Infections

WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 9, 2006--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its lead product candidate, the HIV maturation inhibitor PA-457, was the subject of three presentations at the 13th Conference on Retroviruses and Opportunistic Infections (CROI) held this week in Denver, Colorado.